| Alkylating Agents |
| cyclophosphamide |
Cytoxan injection (Bristol Myers Squibb) |
500mg, 1g, 2g |
pwd for IV inj after reconstitution |
40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every
7–10 days or 3–5mg/kg twice weekly |
| (various) |
25mg, 50mg |
tabs |
1–5mg/kg/day |
| thiotepa |
(various) |
15mg, 30mg |
pwd for IV, intravesical, or intracavitary administration after
reconstitution |
0.3–0.4mg/kg IV once every 1–4 weeks |
| Angiogenesis Inhibitor |
| bevacizumab |
Avastin (Genentech) |
100mg, 400mg |
soln for IV infusion after dilution |
10mg/kg once every 14 days |
| Antibiotics (Cytotoxic) |
| doxorubicin |
Adriamycin (Bedford) |
10mg, 20mg, 50mg |
pwd for IV inj after reconstitution |
Monotherapy: 60–75mg/m2 every 21 days Combination
therapy: 40–60mg/m2 every 21 to 28 days |
| Adriamycin Solution (Bedford) |
2mg/mL |
soln for IV inj |
| epirubicin |
Ellence (Pfizer) |
2mg/mL |
soln for IV infusion |
100–120mg/m2 on Day 1 or divided equally given on Days 1 and 8
of each cycle |
| Antiestrogen |
| tamoxifen |
(various) |
10mg, 20mg |
tabs |
20–40mg/day |
| Soltamox Oral Solution (Savient) |
10mg/5mL |
oral soln |
| toremifene |
Fareston (GTx) |
60mg |
tabs |
60mg once daily |
| Antimetabolites |
| capecitabine |
Xeloda (Roche) |
150mg, 500mg |
tabs |
Monotherapy: 1250mg/m2 twice daily Combination therapy: give with
docetaxel 75mg/m2 IV infused over 1 hour every 3 weeks. |
| fluorouracil |
(various) |
50mg/mL |
soln for IV inj |
12mg/kg once daily for 4 successive days; max 800mg/day |
| gemcitabine |
Gemzar (Lilly) |
200mg, 1g |
pwd for IV infusion after reconstitution |
1250mg/m2 on Days 1 and 8 of each 21 day cycle |
| methotrexate |
Methotrexate injection (Bedford) |
25mg/mL |
soln for IV, IM, intra-arterial, or intra-thecal administration after dilution |
See drug entry and manufacturer's literature |
| 1g |
pwd for IV, IM, intra-arterial, or intra-thecal administration after
dilution |
| Trexall (Duramed) |
5mg, 7.5mg, 10mg, 15mg |
scored tabs |
| Antimicrotubule Agents |
| docetaxel |
Taxotere (Sanofi
Aventis) |
40mg/mL |
soln for IV infusion after dilution |
60–100mg/m2 once every 3 weeks |
| eribulin mesylate |
Halaven (Eisai) |
0.5mg/mL |
soln for IV inj |
1.4mg/m2 IV inj over 2–5min on Days 1 and 8 of each 21 day cycle. |
| ixabepilone |
Ixempra (Bristol Myers Squibb) |
15mg, 45mg |
pwd for IV infusion after constitution and dilution |
40mg/m2 once every 3 weeks |
| paclitaxel |
Abraxane (Abraxis) |
100mg |
IV infusion; inj susp after reconstiution |
260mg/m2 every 3 weeks |
| Taxol (Bristol Myers Squibb) |
6mg/mL |
soln for IV infusion after dilution |
175mg/m2 every 3 weeks |
| vinblastine for injection |
(Bedford) |
10mg |
lyophilized pwd for IV inj or infusion after reconstitution |
5.5–7.4mg/m2 once weekly (see literature) |
| vinblastine injection |
(APP Pharmaceuticals) |
1mg/mL |
soln for IV inj or infusion |
| Aromatase Inhibitor |
| anastrozole |
Arimidex (AstraZeneca) |
1mg |
tabs |
1mg once daily |
| exemestane |
Aromasin
(Pfizer) |
25mg |
tabs |
25mg once daily |
| letrozole |
Femara (Novartis) |
2.5mg |
tabs |
2.5mg once daily |
| Estrogen |
| estradiol |
Estrace (Warner Chilcott) |
0.5mg, 1mg, 2mg |
scored tabs |
10mg 3 times daily for at least 3 months |
| Estrogen Receptor Antagonist |
| fulvestrant |
Faslodex (AstraZeneca) |
50mg/mL |
soln for IM inj |
500mg on days 1, 15, 29, then once per month thereafter |
| GnRH Analogue |
| goserelin |
Zoladex (AstraZeneca) |
3.6mg |
SC implant |
one 3.6mg implant every 28 days |
| Human Epidermal Growth Factor Receptor (HER2)
inhibitor |
| trastuzumab |
Herceptin (Genentech) |
440mg |
lyophilized pwd for IV infusion after reconstitution and dilution |
See drug entry |
| Progestin |
| megestrol acetate |
Megace (Bristol Myers Squibb) |
20mg, 40mg |
scored tabs |
40mg 4 times daily |
| Selective Estrogen Receptor Modulator (SERM) |
| raloxifene |
Evista (Lilly) |
60mg |
tabs |
60mg once daily |
| Tyrosine Kinase Inhibitor |
| lapatinib |
Tykerb (GlaxoSmithKline) |
250mg |
tabs |
See drug entry and manufacturer's literature |